Relevant bibliographies by topics / Analogue du glucose

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Analogue du glucose'

Author: Grafiati
Published: 4 June 2021
Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Analogue du glucose.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Analogue du glucose"

1

Sobhonslidsuk, Abhasnee, Jirachaya Wanichanuwat, Pawin Numthavaj, et al. "Nucleotide Analogue-Related Proximal Renal Tubular Dysfunction during Long-Term Treatment of Chronic Hepatitis B: A Cross-Sectional Study." Gastroenterology Research and Practice 2016 (2016): 1–7. http://dx.doi.org/10.1155/2016/2952635.

Full text
Abstract:
Background. There have been few reports of nucleotide analogue-related renal tubular dysfunction (RTD) in CHB patients. We assessed the prevalence and presentation of nucleotide analogue-related proximal RTD.Methods. A cross-sectional study was performed in CHB patients taking nucleotide analogues. Inclusion criteria were patients who were on adefovir or tenofovir as mono- or add-on therapy with lamivudine (LAM) >1 year. Serum and urine were collected. Fractional excretion of phosphate (FEPO4), uric acid (FEUA), and potassium was calculated. Renal losses were defined based on the criteria: protein (24-hour urine protein >150 mg), glucose (glycosuria with normoglycemia), phosphate (FEPO4>18%), uric acid (FEUA >15%), potassium (renal potassium losses with hypokalemia), and bicarbonate (normal gap acidosis). Subclinical and overt proximal RTD were defined when 2 and ≥3 criteria presented.Results. Ninety-two patients were enrolled. The mean duration of nucleotide analogue taking was55.1±29.6months. Proximal RTD was found in 24 (26.1%) patients (subclinical 15 (16.3%) and overt 9 (9.8%)). The severity of RTD was associated with the duration of nucleotide analogue (P=0.01).Conclusions. The prevalence of proximal RTD in CHB patients taking nucleotide analogues was 26%. The severity of RTD was associated with the treatment duration. Comprehensive testing is necessary for early detecting nucleotide analogue-related nephrotoxicity.
APA, Harvard, Vancouver, ISO, and other styles
2

Greeff, Oppel B. W., Jacob John Van Tonder, Kershlin Naidu, Alicia McMaster, Alet Van Tonder, and Rashem Mothilal. "A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300." South African Family Practice 60, no. 4 (2018): 7–12. http://dx.doi.org/10.4102/safp.v60i4.4903.

Full text
Abstract:
Glucose clamp studies form an integral part of the early development of insulin therapies. Data generated in these studies are used to establish pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the agents, but methodological differences confound comparison of results from different glucose clamp studies. The first part of this series on glucose clamp studies discussed practical tips for the interpretation of glucose clamp studies. The second part of the series compares the PK/PD profiles of longer-acting basal analogue insulins, insulin degludec (IDeg) and insulin glargine U300 (Gla-300). The patient populations for glucose clamp studies with these analogue insulins differ, and therefore direct comparison of the data is not always possible. The maximum duration of action of IDeg is reported as 42 h and that of Gla-300 as 36 h, translating to 24 h coverage. The plasma insulin concentration of IDeg is 56 times that of Gla-300. Results from phase III clinical trials for these analogue insulins confirm the predictability and low within-subject variability observed in glucose clamp studies. Insight into the PK/PD profiles of longer-acting basal analogue insulins allows the treating physician to utilise these characteristics to optimise the treatment of their patients with diabetes.
APA, Harvard, Vancouver, ISO, and other styles
3

Ruyatkina, Lyudmila Alexandrovna, and Maxim Sorokin. "Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance." Diabetes mellitus 20, no. 2 (2017): 142–50. http://dx.doi.org/10.14341/7875.

Full text
Abstract:
Combined glucose-lowering therapy, comprising of basal insulin with glucagon-like peptide-1 (GLP-1) analogues, has become central to the treatment of type 2 diabetes both at the start of insulin therapy, and as an alternative to basal-bolus insulin. The combination of insulin detemir (insulin analogue) with liraglutide (GLP-1 analogue) reduces fasting and postprandial glycaemia, lowers the risk of hypoglycaemia and does not have a negative impact on body weight. In this literature review, the pharmacodynamic and pharmacokinetic profiles, as well as the potential benefits of combined insulin detemir and liraglutide therapy on diabetic nephropathy and high cardiovascular disease risk were determined. Data from randomised clinical trials and the National Registry were used to assess the clinical efficacy of combined insulin detemir and liraglutide therapy. The different mechanistic actions of insulin detemir and liraglutide resulted in an additive glucose-lowering effect, which did not affect the pharmacodynamic and pharmacokinetic profiles of each therapeutic agent.
APA, Harvard, Vancouver, ISO, and other styles
4

Dookhun, Veedeeta, and Andrew J. Bennet. "Synthesis and biological evaluation of a bicyclo[4.1.0]heptyl analogue of glucose-1-phosphate." Canadian Journal of Chemistry 82, no. 9 (2004): 1361–64. http://dx.doi.org/10.1139/v04-109.

Full text
Abstract:
The synthesis of a bicyclo[4.1.0]heptyl analogue of glucose-1-phophate, (1R,2R,3S,4S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)-bicyclo[4.1.0]heptan-2-yl dihydrogen phosphate (5) is reported. The synthetic route chosen started with methyl α-D-glucopyranoside and was accomplished in 11 steps with an overall yield of 3%. Compound 5 was tested as a potential substrate of UTP:α-D-glucose-1-phosphate uridylyltransferase, the enzyme that converts glucose-1-phosphate into UDP-glucose. However, the conformationally restricted glucose-1-phosphate analogue 5 was found to be a weakly binding inhibitor, rather than a substrate, of the yeast transferase (12% inhibition at a concentration of 0.1 mmol L–1).Key words: glucose 1-phosphate, inhibition, UTP:α-D-glucose-1-phosphate uridylyltransferase.
APA, Harvard, Vancouver, ISO, and other styles
5

Stehouwer, C. D. A., W. F. Lems, H. R. A. Fischer, W. H. L. Hackeng, and M. A. B. Naafs. "Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin®)." Acta Endocrinologica 121, no. 1 (1989): 34–40. http://dx.doi.org/10.1530/acta.0.1210034.

Full text
Abstract:
Abstract. Recently somatostatin analogues were successfully used to control insulin-induced hypoglycemia in patients with insulinoma. We observed a transient decrease in glucose levels and symptomatic hypoglycemia after administration of the long-acting somatostatin analogue octreotide (Sandostatin®) in two insulinoma patients. We studied the acute effects of octreotide (administered before breakfast) on blood glucose and glucoregulatory hormones in these patients. In one patient, we studied the effects of glucagon replacement and changing the time of breakfast (relative to octreotide administration) on octreotide-associated changes in blood glucose and glucoregulatory hormones. Compared with control levels, octreotide therapy reduced insulin levels. During hypoglycemia glucagon and growth hormone levels were suppressed, but cortisol levels appropriately increased. The increase in catecholamine levels was normal in one patient, but markedly attenuated in the other. A transient decrease in serum glucose after octreotide was absent after glucagon replacement, but present when breakfast was taken before administration of octreotide. We conclude that in patients with insulinoma, octreotide therapy may be associated with clinically important hypoglycemia, during which counterregulatory hormone secretion may be attenuated.
APA, Harvard, Vancouver, ISO, and other styles
6

Greeff, Oppel B. W., Jacob John Van Tonder, Kershlin Naidu, Alicia McMaster, Alet Van Tonder, and Rashem Mothilal. "A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part one: The principles of glucose clamp studies." South African Family Practice 60, no. 3 (2018): 8–12. http://dx.doi.org/10.4102/safp.v60i3.4874.

Full text
Abstract:
Glucose clamp studies are used to determine pharmacokinetics (PK) and pharmacodynamics (PD) of analogue insulins. With the development of longer-acting basal analogue insulins, including glargine 300 (Gla-300) and insulin degludec (IDeg), results from numerous glucose clamp studies are readily available. However, interpreting PK/PD profiles in a scientifically sound manner can be a challenging feat. This is the first in a series of publications that will suggest practical tips for interpreting and comparing results from glucose clamp studies. Variations in the glucose clamp methodology, duration of clamp studies and glucose clamp targets influence the study design and results significantly. Selection of study populations, including healthy patients or patients with Type 1 or 2 diabetes mellitus, has important implications. The dose of study insulin should reflect that of the general treatment population, and ideally steady-state conditions should be used. During the study the plasma insulin concentration and glucose infusion rate describe the pharmacokinetics and pharmacodynamics of the study insulin. With these practical tips in mind, results of glucose clamp studies can be interpreted in a scientifically correct manner. The next article in this series will discuss the interpretation of PK/PD profiles using two newly developed longer-acting basal analogue insulins: Gla-300 and IDeg.
APA, Harvard, Vancouver, ISO, and other styles
7

Chap, Z., T. Ishida, J. Chou, et al. "First-pass hepatic extraction and metabolic effects of insulin and insulin analogues." American Journal of Physiology-Endocrinology and Metabolism 252, no. 2 (1987): E209—E217. http://dx.doi.org/10.1152/ajpendo.1987.252.2.e209.

Full text
Abstract:
First-pass hepatic extraction of insulin and hepatic and peripheral contributions to hypoglycemia were compared in conscious dogs during portal infusion of insulin A1, B29 diacetyl insulin, or A1-B29 dodecoyl insulin at 7 and 14 pmol X kg-1 X min-1. The liver removed 43 +/- 2% of insulin, 12 +/- 1% of dodecoyl, and 8 +/- 1% of diacetyl insulin, in a single transhepatic circulation. The hypoglycemia induced by insulin and diacetyl insulin and the ensuing glucagon response were greater than that produced by the dodecoyl analogue. Diacetyl insulin primarily increased glucose utilization, dodecoyl insulin solely inhibited hepatic production, and insulin affected both. The lack of hepatic effect of diacetyl insulin during hypoglycemia can be ascribed to greater counterregulation, because under euglycemic clamp conditions, this analogue caused suppression of glucose production. The different patterns of hypoglycemia exhibited can be explained by the combined effects of altered distribution between the liver and peripheral tissues caused by differences in hepatic extraction, the effect of this phenomenon on the counterregulatory response, and the intrinsic biological potency of the analogues.
APA, Harvard, Vancouver, ISO, and other styles
8

Hayasaki, Hana, Masahito Watanabe, Kiyoto Kanbara, et al. "Quenching Effect of Blood on Fluorescent Glucose Analogue NBDG." Acta Histochemica et Cytochemica 29, no. 3 (1996): 207–13. http://dx.doi.org/10.1267/ahc.29.207.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lundgren, D. W., and C. V. Vacca. "Nonmetabolizable glucose analogues and ornithine decarboxylase expression in LLC-PK1 cells." American Journal of Physiology-Cell Physiology 259, no. 4 (1990): C647—C653. http://dx.doi.org/10.1152/ajpcell.1990.259.4.c647.

Full text
Abstract:
This report examines the effect of nonmetabolizable glucose analogues on ornithine decarboxylase (ODC) activity in LLC-PK1 cells. The addition of Na(+)-dependent cotransported glucose analogues, 1-O-methyl-alpha-D-glucopyranoside (alpha-MDG) and 1-O-methyl-beta-D-glucopyranoside, to Earle's balanced salt solution minus glucose (EBSS-G) increased ODC activity five- to sevenfold above basal levels. The passive carrier-mediated transported glucose analogue 3-O-methyl-D-glucopyranose had very little effect on enzyme activity. alpha-MDG increased ODC activity in quiescent but not growing cells. ODC activity increased as a function of both the incubation time in EBSS-G + alpha-MDG and the concentration of alpha-MDG in EBSS-G. Phlorizin significantly reduced the level of enzyme activity induced by alpha-MDG. ODC expression by alpha-MDG was reduced in cells incubated in hypertonic EBSS-G + alpha-MDG. Enzyme activity, in the absence of extracellular organic substrates, was markedly elevated in cells incubated in hypotonic media. It is suggested that an influx of Na+ and/or an increase in cell volume elevates one or more signal transducers that regulate ODC expression.
APA, Harvard, Vancouver, ISO, and other styles
10

Wu, Hui, Chunhua Sui, Hui Xu, et al. "The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp." Journal of Diabetes Research 2014 (2014): 1–10. http://dx.doi.org/10.1155/2014/524517.

Full text
Abstract:
Objective. Glucagon-like peptide-1 (GLP-1) analogues (e.g., exenatide) increase insulin secretion in diabetes but less is known about their effects on glucose production or insulin-stimulated glucose uptake in peripheral tissues.Methods. Four groups of Sprague-Dawley rats were studied: nondiabetic (control, C); nondiabetic + exenatide (C + E); diabetic (D); diabetic + exenatide (D + E) with diabetes induced by streptozotocin and high fat diet. Infusion of 3-3H-glucose and U-13C-glycerol was used to measure basal rates of appearance (Ra) of glucose and glycerol and gluconeogenesis from glycerol (GNG). During hyperinsulinemic-euglycemic clamp, glucose uptake into gastrocnemius muscles was measured with 2-deoxy-D-14C-glucose.Results. In the diabetic rats, exenatide reduced the basalRaof glucose (P<0.01) and glycerol (P<0.01) and GNG (P<0.001). During the clamp,Raof glucose was also reduced, whereas the rate of disappearance of glucose increased and there was increased glucose uptake into muscle (P<0.01) during the clamp. In the nondiabetic rats, exenatide had no effect.Conclusion. In addition to its known effects on insulin secretion, administration of the GLP-1 analogue, exenatide, is associated with increased inhibition of gluconeogenesis and improved glucose uptake into muscle in diabetic rats, implying improved hepatic and peripheral insulin sensitivity.
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Analogue du glucose"

1

Elamin, Ahmed Abu Baker. "Studies on the short-acting insulin analogue lispro." Thesis, University of Newcastle Upon Tyne, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.310125.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vollaire, Julien. "Développement d'une nouvelle technique de mesure de la résistance à l'insuline avec un traceur du transport du glucose, le [125I]-6-Déoxy-6-Iodo-D-glucose : étude réalisée chez le rat." Phd thesis, Grenoble, 2010. http://www.theses.fr/2010GRENS019.

Full text
Abstract:
L'insulino-résistance (IR), est un défaut métabolique clef dans le développement de nombreuses anomalies métaboliques, et augmente considérablement le risque de maladies cardiovasculaires. Le dépistage précoce de l'IR, est donc d'un intérêt clinique majeur. Parmi les techniques de mesure de l'IR, aucune n'est applicable en routine clinique. L'UMR_S 877 a développé un analogue iodé du glucose, le [123I]-6-déoxy-6-iodo-D-glucose (6DIG), traceur pur du transport du glucose. Un protocole de mesure a été développé pour étudier le transport du 6DIG dans le cœur, et fournir un index R d'IR cardiaque. L'objectif de mon travail consiste à valider l'index d'IR cardiaque, à développer une méthode de mesure de l'IR dans le muscle squelettique avec le 6DIG, et de regrouper ces deux méthodes en un seul protocole transposable chez l'homme. Les résultats montrent que l'index cardiaque est reproductible et sensible, il est validé. Un descripteur empirique (DE), basé sur l'analyse des cinétiques tissulaires a été développé. Il est également reproductible et sensible. Le transport du 6DIG dans le muscle squelettique peut être modélisé et fournir un index d'IR musculaire. Un DE musculaire corrélé aux valeurs d'index du modèle mathématique a été recherché. Les index d'IR cardiaques et musculaires corrèlent significativement avec le GIR, obtenu avec la méthode de référence de mesure de l'IR, le clamp euglycémique hyperinsulinémique. Les deux DE, mesurés simultanément lors d'un même protocole, sont reproductibles et sensibles. Ces résultats permettent d'envisager l'utilisation du 6DIG chez l'homme, et pour des études physiopathologiques chez l'animal<br>Insulin resistance (IR) is a key defect in the development of many metabolic complications, such as Metabolic Syndrome and type 2 diabetes. Assessment of IR is of great clinical interest. There are no accurate and convenient procedure for insulin resistance measurement available in clinical practice. [123I]6-deoxy-6-iodo-D-glucose (6DIG) has been developed as a new tracer of glucose transport. An experimental protocol and a compartmental model were developed to study 6DIG transport in myocardium, and provide a cardiac IR index. The aim of this study was first to valide this cardiac IR index, second to develop a protocol for muscle IR index with 6DIG, and third to group this two protocols in one, transposable in humans. Results show that cardiac IR index is reproducible and sensitive. An empirical descriptor (ED), based on an analysis of tissue-activity curves has been develop. It is reproducible and sensitive. Mathematical modelisation permit to estimate 6DIG transport in skeletal muscle, and provide a muscle IR index. An ED, correlated with index values, has been developed. Skeletal muscle and myocardic IR index are significantly correlated with GIR, provided by the gold standard assessment of IR, the hyperinsulinaemic glucose clamp. ED are well correlated with GIR but no significantly. The two ED measured during the same experimental protocol, are reproducible and sensitive. Results are very encouraging for further use in Nuclear Medicine in humans, and for physiopathological studies in animals
APA, Harvard, Vancouver, ISO, and other styles
3

Ogier, Lionel. "Synthèse de nouveaux analogues iodés du D-glucose." Université Joseph Fourier (Grenoble), 1998. http://www.theses.fr/1998GRE10264.

Full text
Abstract:
Chez l'homme, de nombreuses pathologies sont liees a des dysfonctionnements du transport cellulaire du d-glucose. Les techniques d'imagerie etant un outil precieux pour detecter ces anomalies de transport, la synthese d'analogues du d-glucose radiomarques a l'iode (emetteur gamma) et utilisables en imagerie spect, a ete entreprise selon deux approches : la premiere repose sur l'utilisation du motif beta-iodoethoxyle qui a ete introduit sur diverses positions (1, 4, 5 et 6) du glucose. La seconde consiste a conserver tous les hydroxyles du glucose en introduisant le motif iode a partir des carbones du squelette. Ceci a ete effectue avec un motif iodomethyle sur les positions 3 et 6 ainsi que para-iodophenyle sur cette derniere. Tous les derives prepares ont fait l'objet d'une evaluation biologique, au moins preliminaire, sans toutefois presenter les proprietes d'un traceur du d-glucose, a l'exception du 6-deoxy-6-iodo-d-glucose (6-dig). Ce dernier, dont l'evaluation biologique sera poursuivie, a pu etre prepare a une echelle multi-grammes.
APA, Harvard, Vancouver, ISO, and other styles
4

Moolman, Lukas Johannes. "The effect of snacking on continuously monitored glucose concentrations in analogue insulin basal bolus treatment regimens." Diss., University of Pretoria, 2013. http://hdl.handle.net/2263/40694.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Henry, Christelle. "Etude du comportement biologique de nouveaux analogues iodés du glucose, proposés comme marqueurs de la captation du glucose." Université Joseph Fourier (Grenoble), 1995. http://www.theses.fr/1995GRE10029.

Full text
Abstract:
Le glucose est un substrat energetique pour la totalite des tissus de l'organisme et l'appreciation de sa captation revet une grande importance en medecine en particulier en cardiologie, en neurologie et en cancerologie. Actuellement, pour etudier le metabolisme du glucose chez l'homme, on utilise le #1#8f fluorodeoxyglucose (fdg). Le fdg presente des inconvenients majeurs qui limitent son emploi a 3 centres en france. C'est pourquoi notre travail s'est oriente vers la recherche de nouveaux analogues du glucose marques a l'iode radioactif emetteur et utilisables dans tous les services de medecine nucleaire. Trois modeles experimentaux ont ete choisis: la biodistribution chez la souris (in vivo), le cur isole et perfuse de rat (ex vivo) et les erythrocytes humains en suspension (in vitro). Sur l'ensemble des modeles biologiques, nous avons etabli les protocoles experimentaux et les valeurs de reference de la captation du 1-#1#4c-2-deoxy-d-glucose (2-dg) qui entre dans la cellule par le transporteur du d-glucose et du l-#1#4c-glucose qui entre par diffusion passive. Des analogues du glucose marques a l'iode 123 en position -1, -2, -3 ou -6 de la molecule de glucose ont ete etudies sur les differents modeles experimentaux et selon les protocoles valides avec les molecules de reference. Pour servir a l'etude de la captation cellulaire du glucose, l'analogue iode doit imperativement entrer dans la cellule grace au transporteur du glucose. Trois analogues du glucose (big7, big9 et bigac1) se sont reveles potentiellement tres interessants puisque leur fixation est augmentee en presence d'insuline et diminuee en presence d'inhibiteur du transport du glucose. Big7 et big9 ont presente un comportement biologique comparable a celui du 3-o-methyl-d-glucose qui entre dans la cellule comme le glucose sans y etre metabolise. De plus, injectes chez le chien in vivo, ces analogues iodes du glucose permettent d'obtenir des images scintigraphique de bonne qualite
APA, Harvard, Vancouver, ISO, and other styles
6

Koumanov, Françoise. "Evaluation biologique d'analogues iodés du glucose : étude de leurs interactions avec le transporteur." Université Joseph Fourier (Grenoble), 1996. http://www.theses.fr/1996GRE10115.

Full text
Abstract:
De nombreux etats pathologiques, tels le diabete, les maladies cerebrales, l'ischemie myocardique et le cancer, sont associes a des troubles dans le transport ou le metabolisme intracellulaire du glucose. L'appreciation in vivo chez l'homme des variations pathologiques de la captation du glucose revet donc une grande importance en medecine. Pour ces raisons nous avons oriente notre travail vers la recherche de nouveaux analogues du glucose marques a l'iode 123, un radioelement emetteur et utilisables dans tous les services de medecine nucleaire. Pour proceder a l'evaluation biologique de ces analogues iodes du glucose nous avons choisi deux modeles experimentaux: la culture primaire de cardiomyocytes de rats nouveau-nes et la souris in vivo. Ces modeles experimentaux ont ete valides et des protocoles experimentaux pour l'etude des nouveaux analogues du glucose ont ete etablis avec l'aide de trois traceurs de reference de la captation du glucose par les cellules: le #1#4c2-deoxy-d-glucose, le #1#4c3-o-methyl-d-glucose (3-omg) et le #1#4cl-glucose. Dix analogues du glucose, marques a l'iode 123 en position 1, 2, 3 ou 6 de la molecule du glucose ont ete synthetises et etudies sur nos differents modeles experimentaux. Parmi ces analogues trois ont montre des proprietes interessantes. Le 6-deoxy-6-iodo-d-glucose (6dig) a montre un comportement tres proche de celui du 3-omg et s'est donc revele etre un excellent traceur du transport net du glucose par l'intermediaire du transporteur du glucose. Le -methyl-6-deoxy-6-iodo-d-glucose (mdig) a aussi montre un comportement semblable a celui du 3-omg, mais cependant, la specificite de son interaction avec le transporteur du glucose semble plus faible comparee a celle du 6dig. Le 2,3,4,6-tetra-o-acetyl-2'iodoethyl -d-glucopyranoside (1paig1) a montre des caracteristiques laissant supposer qu'il pourrait etre un bon marqueur des transporteurs du glucose, se fixant sur ceux-ci probablement du cote intracellulaire. Son comportement biologique a ete compare a celui de la cytochalasine b, un marqueur des transporteurs du glucose, et les deux molecules ont montre un comportement biologique similaire. Les resultats obtenus avec ces trois molecules sont tres encourageants puisque c'est la premiere fois que l'on observe une interaction specifique entre un analogue iode du glucose et le transporteur. De plus, injectees chez le chien in vivo, ces molecules permettent l'acquisition d'images scintigraphiques de bonne qualite
APA, Harvard, Vancouver, ISO, and other styles
7

Bresciani, Stefano. "Stereospecific dehydroxyfluorination and the synthesis of trifluoro D-hexose sugar analogues." Thesis, University of St Andrews, 2011. http://hdl.handle.net/10023/1878.

Full text
Abstract:
This thesis describes stereospecific fluorination reactions, and addresses the synthesis of fluorosugars. In Chapter 1, the influence of fluorine on the physical properties of organic molecules, as well as its stereoelectronic effects, are introduced. Furthermore, an overview of nucleophilic and electrophilic fluorination reactions is given. Chapter 2 describes the dehydroxyfluorination of allylic alcohol diastereoisomers 155a and 155b, which can proceed either by direct or allylic fluorination. The regio- and stereo- selectivities were also assessed. Chapter 3 outlines the synthesis of the novel trifluoro D-glucose analogue 193 and trifluoro D-altrose analogue 216. The transport of these hexose analogues across the red blood cell membranes was then explored, to investigate the influence of polarity versus hydrogen bonding ability in carbohydrate-protein interactions. Chapter 4 describes the development and optimisation of Bio’s methodology, to promote stereospecific dehydroxyfluorination of benzylic alcohols (R)-213 and (R)-227 by addition of TMS-amine additives 226 and 229. And finally Chapter 5 reports the experimental procedures as well as the characterisation and the crystallographic data of the molecules prepared in this thesis.
APA, Harvard, Vancouver, ISO, and other styles
8

Perret, Pascale. "Études biologiques de nouveaux analogues iodés du glucose et validation du 6-deoxy-6-iodo-d-glucose (6DIG) comme traceur du transport du glucose in vivo." Université Joseph Fourier (Grenoble), 1999. http://www.theses.fr/1999GRE19006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hunter, Kerry. "Actions and antidiabetic properties of novel long-acting glucose-dependent insulinotropic polypeptide analogues." Thesis, University of Ulster, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.414988.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gault, Victor Alan. "Actions and antidiabetic potential of amino terminally modified analogues of glucose dependent insulinotropic polypeptide." Thesis, University of Ulster, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.274418.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Analogue du glucose"

1

Gault, Victor Alan. Actions and antidiabetic potential of amino-terminally modified analogues of glucose-dependent insulinotropic polypeptide. The author], 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Irwin, Nigel. Novel analogues of glucose-dependent insulinotropic polypeptide (GIP) for potential treatment of type 2 diabetes. The Author], 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Al-Nahhas, Adil, and Imene Zerizer. Nuclear medicine. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0070.

Full text
Abstract:
The application of nuclear medicine techniques in the diagnosis and management of rheumatological conditions relies on its ability to detect physiological and pathological changes in vivo, usually at an earlier stage compared to structural changes visualized on conventional imaging. These techniques are based on the in-vivo administration of a gamma-emitting radionuclide whose distribution can be monitored externally using a gamma camera. To guide a radionuclide to the area of interest, it is usually bound to a chemical label to form a 'radiopharmaceutical'. There are hundreds of radiopharmaceuticals in clinical use with different 'homing' mechanisms, such as 99 mTc HDP for bone scan and 99 mTc MAA for lung scan. Comparing pre- and posttherapy scans can aid in monitoring response to treatment. More recently, positron emission tomography combined with simultaneous computed tomography (PET/CT) has been introduced into clinical practice. This technique provides superb spatial resolution and anatomical localization compared to gamma-camera imaging. The most widely used PET radiopharmaceutical, flurodeoxyglucose (18F-FDG), is a fluorinated glucose analogue, which can detect hypermetabolism and has therefore been used in imaging and monitoring response to treatment of a variety of cancers as well as inflammatory conditions such as vasculitis, myopathy, and arthritides. Other PET radiopharmaceuticals targeting inflammation and activated macrophages are becoming available and could open new frontiers in PET imaging in rheumatology. Nuclear medicine procedures can also be used therapeutically. Beta-emitting radiopharmaceuticals, such as yttrium-90, invoke localized tissue damage at the site of injection and can be used in the treatment of synovitis.
APA, Harvard, Vancouver, ISO, and other styles
4

Stafstrom, Carl E., and Thomas P. Sutula. 2-Deoxyglucose. Edited by Dominic P. D’Agostino. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190497996.003.0036.

Full text
Abstract:
Metabolic regulation of excitability is increasingly appreciated as a strategy to control seizures and reduce pathogenesis. Inhibiting or bypassing glycolysis may be one way in which the ketogenic diet suppresses seizures. 2-deoxy-D-glucose (2DG) is a glucose analog that partially inhibits glycolysis and has antiseizure effects in several acute and chronic seizure models. The mechanisms underlying the acute and chronic effects of 2DG are being investigated. Preliminary studies provide evidence that the acute anticonvulsant actions of 2DG involve activity-dependent presynaptic suppression of excitatory synaptic transmission during network synchronization. The chronic effects of 2DG entail reduction of the expression of brain-derived neurotrophic factor and its receptor, tyrosine kinase B. Preclinical toxicology studies demonstrate that 2DG has a favorable toxicity profile at doses effective for seizure protection. Currently available preclinical studies support 2DG as a novel first-in-class metabolic treatment for epilepsy with an antiglycolytic mechanism distinct from all other anticonvulsants.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Analogue du glucose"

1

Murata, Rei, Yuki Takada, Hiroyuki Takuwa, et al. "Vessel Specific Imaging of Glucose Transfer with Fluorescent Glucose Analogue in Anesthetized Mouse Cortex." In Advances in Experimental Medicine and Biology. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0620-8_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Villarreal, Paula, Rahul Pal, and Gracie Vargas. "In Vivo Epithelial Metabolic Imaging Using a Topical Fluorescent Glucose Analog." In Cell Tracking. Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-0364-2_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhang, Xian-En. "Simultaneous Determination of Glucose and Analogous Disaccharides by Dual-Electrode Enzyme Sensor System." In Biosensors and Their Applications. Springer US, 2000. http://dx.doi.org/10.1007/978-1-4615-4181-3_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Teixeira, Miguel Lima, Camilo Velez, Dian Li, and João Goes. "Microneedle Based ECG – Glucose Painless MEMS Sensor with Analog Front End for Portable Devices." In IFIP Advances in Information and Communication Technology. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56077-9_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Laczkó-Hollósi, Ilona, Miklós Hollósi, Virginia M. Y. Lee, and Henry H. Mantsch. "Conformational change of a synthetic amyloid analogue des[Ala21,30]A42 upon binding to octyl glucoside micelles." In Peptides 1992. Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1470-7_235.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hoffman, Robert M. "Is the Hoffman Effect for Methionine Overuse Analogous to the Warburg Effect for Glucose Overuse in Cancer?" In Methods in Molecular Biology. Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-8796-2_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

del Pozo, E., S. W. J. Lamberts, C. Sieber, and A. Gomez-Pan. "Effect of a Long-Acting Somatostatin Analog (Sms 201–995) on Glucose Homeostasis in Type I Diabetes and in Acromegaly." In Somatostatin. Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5326-3_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hovorka, Roman. "Closing the loop." In Oxford Textbook of Endocrinology and Diabetes. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235292.003.1455.

Full text
Abstract:
The standard therapy of type 1 diabetes is based on multiple daily injections of short- and long acting-insulin analogues accompanied by blood glucose self-monitoring. However, treatment goals identified by the Diabetes Control and Complications Trial are difficult to achieve due, at least in part, to a high risk of hypoglycaemia associated with many currents forms of intensive insulin therapy. Recent technological developments in real-time subcutaneous continuous glucose monitoring (CGM), combined with the continuous subcutaneous insulin infusion (CSII), could potentially reduce this risk. Since late 1990s at least five continuous or semicontinuous glucose monitors have received regulatory approval (1). CGM has been shown to improve glycaemic control in adults with type 1 diabetes, although apparent barriers to effectiveness in children and adolescents remain to be identified (see Chapter 13.4.9.1) (2). The availability of commercial CGM devices has reinvigorated research towards closed-loop systems (3-6), in which insulin is delivered according to real-time needs, as opposed to open-loop systems, which lack real-time responsiveness to changing glucose concentrations. Closed-loop insulin delivery, in which the insulin delivery is informed by the measured glucose concentrations has the potential gradually to revolutionize the management of type 1 diabetes by reducing or eliminating the risk of hypoglycaemia while achieving near-normal glucose levels. A closed-loop system, also called the ‘artificial pancreas’, comprises three components: a CGM device to measure real-time glucose concentration, a titrating algorithm to compute the amount of insulin needed, and an insulin pump delivering a rapid-acting insulin analogue (see Fig. 13.4.9.2.1). Only a few prototypes have been developed. Progress has been hindered by suboptimal accuracy and reliability of CGM devices, the relatively slow absorption of subcutaneously administered ‘rapid’-acting insulin analogues, and the lack of adequate control algorithms. So far, testing has been confined to the clinical setting. However, a concentrated effort promises an accelerated progress towards home testing of closed-loop systems. The research focus centres on systems utilizing subcutaneous glucose sensing and subcutaneous insulin delivery. This approach has the greatest potential for a near-future commercial exploitation, although other approaches utilizing intraperitoneal or intravenous sensing/delivery are, in principle, also feasible.
APA, Harvard, Vancouver, ISO, and other styles
9

Al-Nahhas, Adil, and Imene Zerizer. "Nuclear Medicine Imaging and Therapy in Rheumatology." In Oxford Textbook of Rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0070_update_001.

Full text
Abstract:
The application of nuclear medicine techniques in the diagnosis and management of rheumatological conditions relies on its ability to detect physiological and pathological changes in vivo, usually at an earlier stage compared to structural changes visualized on conventional imaging. These techniques are based on the in-vivo administration of a gamma-emitting radionuclide whose distribution can be monitored externally using a gamma camera. To guide a radionuclide to the area of interest, it is usually bound to a chemical label to form a ’radiopharmaceutical’. There are hundreds of radiopharmaceuticals in clinical use with different ’homing’ mechanisms, such as <sup>99 m</sup>Tc HDP for bone scan and <sup>99 m</sup>Tc MAA for lung scan. Comparing pre- and posttherapy scans can aid in monitoring response to treatment. More recently, positron emission tomography combined with simultaneous computed tomography (PET/CT) has been introduced into clinical practice. This technique provides superb spatial resolution and anatomical localization compared to gamma-camera imaging. The most widely used PET radiopharmaceutical, flurodeoxyglucose (<sup>18</sup>F-FDG), is a fluorinated glucose analogue, which can detect hypermetabolism and has therefore been used in imaging and monitoring response to treatment of a variety of cancers as well as inflammatory conditions such as vasculitis, myopathy, and arthritides. Other PET radiopharmaceuticals targeting inflammation and activated macrophages are becoming available and could open new frontiers in PET imaging in rheumatology. Nuclear medicine procedures can also be used therapeutically. Beta-emitting radiopharmaceuticals, such as yttrium-90, invoke localized tissue damage at the site of injection and can be used in the treatment of synovitis.
APA, Harvard, Vancouver, ISO, and other styles
10

Chlup, Rudolf, Richard Kaňa, Lada Hanáčková, Hana Zálešáková, and Blanka Doubravová. "Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020." In Type 2 Diabetes [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96237.

Full text
Abstract:
This overview summarizes the evolution of pathophysiologic treatment of diabetes type 2 (T2D) in the period of the last 40 years. Randomized Controlled Trials (RCT) and Real World Evidence (RWE) studies resulted in recent Statements of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) in the year 2020. Case reports and studies of a single-centre in Czech Republic are reported. The authors demonstrate the impact of (1) multiple doses of rapid insulin, (2) multiple doses of rapid or ultrarapid insulin analogs (3) continuous subcutaneous insulin infusion (CSII) (4) incretin receptor agonists, (5) fixed combination of insulin degludec with liraglutide (IDegLira) and (6) SGLT2 inhibitor dapagliflozin, on plasma glucose concentration, HbA1c, body mass and patient satisfaction. The importance of therapeutic patients´ education and technology (personal glucometers, continuous/flash glucose monitors, insulin pens/pumps) is emphasized. Most of the observations were already published. Hence, individually adopted education, lifstyle, technical equipment, incretin receptor agonists and/or metformin and/or gliflozins and/or insulin analogs appear to be the core of an effective pathophysiologic approach. Scientific conclusions from RCTs, RWE trials and own clinical case reports may prevail over clinical inertia and induce early implementation of effective methods into routine T2D treatment.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Analogue du glucose"

1

He, Yun, Yawei Qu, Jing Bai, and Haifeng Liu. "Wide-field endoscopic fluorescence imaging for gastrointestinal tumor detection with glucose analogue." In SPIE Translational Biophotonics, edited by Tomasz S. Tkaczyk. SPIE, 2014. http://dx.doi.org/10.1117/12.2057696.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Klimontov, V. V., E. A. Koroleva, and O. N. Fazullina. "Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes." In 2018 11th International Multiconference Bioinformatics of Genome Regulation and Structure\Systems Biology (BGRS\SB). IEEE, 2018. http://dx.doi.org/10.1109/csgb.2018.8544728.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hrmova, Maria, Joseph N. Varghese, Ross De Gori, et al. "CATALYTIC MECHANISMS AND THE BASIS OF SUBSTRATE SPECIFICITY OF BETA-D-GLUCAN GLUCOHYDROLASES: CRYSTAL STRUCTURES OF THE ENZYME IN COMPLEX WITH GLUCOSIDE INHIBITORS AND SUBSTRATE ANALOGUES." In XXIst International Carbohydrate Symposium 2002. TheScientificWorld Ltd, 2002. http://dx.doi.org/10.1100/tsw.2002.467.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Krisztina, Kovacs, Christina Decatur, Jing Yuqi, Timothy Murray, and Jaime R. Merchan. "Abstract 2332: The glucose analog 2-DG selectively inhibits AKT and ERK in endothelial cells via interference of N-linked glycosylation and induces endothelial cell apoptosis in vitro and in vivo." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography